GTCBio ImmunoTX 2017 Abstract

  • January 31, 2017

“New paradigms of immunophenotyping for toxicological assessments in preclinical and clinical pharmaceutical studies”

Three to six color TBNK panels assessing T-, B-lymphocytes, and NK cells (CD3, CD4, CD8, CD16, and CD20) are staples of both preclinical and clinical flow cytometry laboratories. Previously up to eight color flow cytometry was only available during the research phases of drug development. In recent years, twelve color instruments have become commonplace in the clinical laboratory. As new biological classes of pharmaceutical drugs are being developed for more complex mechanisms, a need arises to have the off the shelf subsets analyses available with drop in slots to customize the needs of an individual drug program, typically for receptor occupancy.


The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients

  • December 1, 2016

The potent and selective JAK1 inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study in combination with methotrexate (MTX) in active rheumatoid arthritis (RA) patients with inadequate response to MTX (DARWIN 1 study). The data gathered demonstrates a systemic anti-inflammatory activity of filgotinib in line with its clinical efficacy observed in RA patients.


Preclinical Characterization of Humoral Immune Responses

  • May 3, 2016

Recent preclinical studies have demonstrated the use of properly folded trimeric HIV-1 envelope proteins in eliciting broadly neutralizing antibodies (bNAbs). These bNAbs target highly conserved sites on the envelope glycoprotein of HIV which consists of trimeric units of non-covalently associated surface subunit, gp120, and transmembrane subunit, gp41. Understanding the type of antibody responses generated by such envelope proteins may be important for the development of an effective HIV-1 vaccine.